Global GP Vaccination Market

GP Vaccination Comprehensive Study by Type (DNA, Non-replicating Viral Vector, RNA, Others), End-users (Adults, Children), Vaccine (Corbevax Vaccine, Covaxin Vaccine, Covishield Vaccine, Sputnik Light Vaccine, Others) Players and Region - Global Market Outlook to 2030

GP Vaccination Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About GP Vaccination
A GP vaccination is a vaccine meant to grant received immunity in opposition to extreme acute respiratory syndrome coronavirus two (SARS-CoV-2), the virus that reasons coronavirus disorder 2019 (COVID19). A vaccine is an organic coaching that affords lively received immunity to a precise infectious disease. A vaccine usually consists of an agent that resembles a disease-causing microorganism and is regularly made from weakened or killed types of the microbe, its toxins, or one of its floor proteins. The agent stimulates the body's immune machine to understand the agent as a threat, smash it, and to similarly apprehend and smash any of the microorganisms related with that agent that it might also come upon in the future. The COVID19 vaccines are broadly credited for their function in decreasing the severity and loss of life precipitated via COVID19. Many international locations have carried out phased distribution plans that prioritize these at very best chance of complications, such as the elderly, and these at high danger of publicity and transmission, such as healthcare workers.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global GP Vaccination market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKine (United Kingdom), Pfizer (United States), Johnson & Johnson (United States), Heat Biologics (United States), Sanofi (France), Takis Biotech (Italy), Zydus Cadila (India), Codagenix (United States), GeoVax (United States) and Bravovax (China) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Altimmune (United States), Vaxart (United States), Clover Biopharmaceuticals (China) and ImmunoPrecise (Canada).

Segmentation Overview
AMA Research has segmented the market of Global GP Vaccination market by Type (DNA, Non-replicating Viral Vector, RNA and Others) and Region.



On the basis of geography, the market of GP Vaccination has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-users, the sub-segment i.e. Adults will boost the GP Vaccination market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Vaccine, the sub-segment i.e. Corbevax Vaccine will boost the GP Vaccination market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing demand for Low-priced Vaccines and Rising Focus on the Development of New and Improved Vaccines

Market Growth Drivers:
High Prevalence of Diseases Requiring Administration of Vaccines and Emerging Use of Vaccines for Different Infectious Diseases

Challenges:
Inequitable access to Vaccines and Increase the Risks and Failure Rate of Delivering A Safe, Effective Vaccine

Restraints:
Side Effects Include Pain at the Injection Site, Fever, Fatigue, Headache, Muscle Pain, Chills and Diarrhoea and High Cost associated with Vaccine

Opportunities:
Increasing Healthcare Expenditure

Market Leaders and their expansionary development strategies
In 2021, partnered with Anglo-Swedish drugmaker AstraZeneca and Serum Institute of India on the international improvement and distribution of Oxford’s COVID-19 vaccine, if medical trials show successful.
In 2021, Beijing Institute of Biological Products, a unit of China National Biotech Group Co Ltd (CNBG) has collaborated with China National Biotec Group Company (Sinopharm).
The U.S. Food and Drug Administration issued the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus ailment 2019 (COVID-19) brought about through extreme acute respiratory syndrome coronavirus two (SARS-CoV-2) in persons sixteen years of age and older. The emergency use authorization lets in the Pfizer-BioNTech COVID-19 Vaccine to be allotted in the U.S.

Key Target Audience
GP Vaccination Provider, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • DNA
  • Non-replicating Viral Vector
  • RNA
  • Others
By End-users
  • Adults
  • Children

By Vaccine
  • Corbevax Vaccine
  • Covaxin Vaccine
  • Covishield Vaccine
  • Sputnik Light Vaccine
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence of Diseases Requiring Administration of Vaccines and Emerging Use of Vaccines for Different Infectious Diseases
    • 3.3. Market Challenges
      • 3.3.1. Inequitable access to Vaccines
      • 3.3.2. Increase the Risks and Failure Rate of Delivering A Safe, Effective Vaccine
    • 3.4. Market Trends
      • 3.4.1. Growing demand for Low-priced Vaccines
      • 3.4.2. Rising Focus on the Development of New and Improved Vaccines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global GP Vaccination, by Type, End-users, Vaccine and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global GP Vaccination (Value)
      • 5.2.1. Global GP Vaccination by: Type (Value)
        • 5.2.1.1. DNA
        • 5.2.1.2. Non-replicating Viral Vector
        • 5.2.1.3. RNA
        • 5.2.1.4. Others
      • 5.2.2. Global GP Vaccination by: End-users (Value)
        • 5.2.2.1. Adults
        • 5.2.2.2. Children
      • 5.2.3. Global GP Vaccination by: Vaccine (Value)
        • 5.2.3.1. Corbevax Vaccine
        • 5.2.3.2. Covaxin Vaccine
        • 5.2.3.3. Covishield Vaccine
        • 5.2.3.4. Sputnik Light Vaccine
        • 5.2.3.5. Others
      • 5.2.4. Global GP Vaccination Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global GP Vaccination (Volume)
      • 5.3.1. Global GP Vaccination by: Type (Volume)
        • 5.3.1.1. DNA
        • 5.3.1.2. Non-replicating Viral Vector
        • 5.3.1.3. RNA
        • 5.3.1.4. Others
      • 5.3.2. Global GP Vaccination by: End-users (Volume)
        • 5.3.2.1. Adults
        • 5.3.2.2. Children
      • 5.3.3. Global GP Vaccination by: Vaccine (Volume)
        • 5.3.3.1. Corbevax Vaccine
        • 5.3.3.2. Covaxin Vaccine
        • 5.3.3.3. Covishield Vaccine
        • 5.3.3.4. Sputnik Light Vaccine
        • 5.3.3.5. Others
      • 5.3.4. Global GP Vaccination Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Australia
          • 5.3.4.2.6. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global GP Vaccination (Price)
      • 5.4.1. Global GP Vaccination by: Type (Price)
  • 6. GP Vaccination: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKine (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Heat Biologics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Takis Biotech (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Zydus Cadila (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Codagenix (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GeoVax (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bravovax (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global GP Vaccination Sale, by Type, End-users, Vaccine and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global GP Vaccination (Value)
      • 7.2.1. Global GP Vaccination by: Type (Value)
        • 7.2.1.1. DNA
        • 7.2.1.2. Non-replicating Viral Vector
        • 7.2.1.3. RNA
        • 7.2.1.4. Others
      • 7.2.2. Global GP Vaccination by: End-users (Value)
        • 7.2.2.1. Adults
        • 7.2.2.2. Children
      • 7.2.3. Global GP Vaccination by: Vaccine (Value)
        • 7.2.3.1. Corbevax Vaccine
        • 7.2.3.2. Covaxin Vaccine
        • 7.2.3.3. Covishield Vaccine
        • 7.2.3.4. Sputnik Light Vaccine
        • 7.2.3.5. Others
      • 7.2.4. Global GP Vaccination Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global GP Vaccination (Volume)
      • 7.3.1. Global GP Vaccination by: Type (Volume)
        • 7.3.1.1. DNA
        • 7.3.1.2. Non-replicating Viral Vector
        • 7.3.1.3. RNA
        • 7.3.1.4. Others
      • 7.3.2. Global GP Vaccination by: End-users (Volume)
        • 7.3.2.1. Adults
        • 7.3.2.2. Children
      • 7.3.3. Global GP Vaccination by: Vaccine (Volume)
        • 7.3.3.1. Corbevax Vaccine
        • 7.3.3.2. Covaxin Vaccine
        • 7.3.3.3. Covishield Vaccine
        • 7.3.3.4. Sputnik Light Vaccine
        • 7.3.3.5. Others
      • 7.3.4. Global GP Vaccination Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Australia
          • 7.3.4.2.6. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global GP Vaccination (Price)
      • 7.4.1. Global GP Vaccination by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. GP Vaccination: by Type(USD Million)
  • Table 2. GP Vaccination DNA , by Region USD Million (2018-2023)
  • Table 3. GP Vaccination Non-replicating Viral Vector , by Region USD Million (2018-2023)
  • Table 4. GP Vaccination RNA , by Region USD Million (2018-2023)
  • Table 5. GP Vaccination Others , by Region USD Million (2018-2023)
  • Table 6. GP Vaccination: by End-users(USD Million)
  • Table 7. GP Vaccination Adults , by Region USD Million (2018-2023)
  • Table 8. GP Vaccination Children , by Region USD Million (2018-2023)
  • Table 9. GP Vaccination: by Vaccine(USD Million)
  • Table 10. GP Vaccination Corbevax Vaccine , by Region USD Million (2018-2023)
  • Table 11. GP Vaccination Covaxin Vaccine , by Region USD Million (2018-2023)
  • Table 12. GP Vaccination Covishield Vaccine , by Region USD Million (2018-2023)
  • Table 13. GP Vaccination Sputnik Light Vaccine , by Region USD Million (2018-2023)
  • Table 14. GP Vaccination Others , by Region USD Million (2018-2023)
  • Table 15. South America GP Vaccination, by Country USD Million (2018-2023)
  • Table 16. South America GP Vaccination, by Type USD Million (2018-2023)
  • Table 17. South America GP Vaccination, by End-users USD Million (2018-2023)
  • Table 18. South America GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 19. Brazil GP Vaccination, by Type USD Million (2018-2023)
  • Table 20. Brazil GP Vaccination, by End-users USD Million (2018-2023)
  • Table 21. Brazil GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 22. Argentina GP Vaccination, by Type USD Million (2018-2023)
  • Table 23. Argentina GP Vaccination, by End-users USD Million (2018-2023)
  • Table 24. Argentina GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 25. Rest of South America GP Vaccination, by Type USD Million (2018-2023)
  • Table 26. Rest of South America GP Vaccination, by End-users USD Million (2018-2023)
  • Table 27. Rest of South America GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 28. Asia Pacific GP Vaccination, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific GP Vaccination, by Type USD Million (2018-2023)
  • Table 30. Asia Pacific GP Vaccination, by End-users USD Million (2018-2023)
  • Table 31. Asia Pacific GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 32. China GP Vaccination, by Type USD Million (2018-2023)
  • Table 33. China GP Vaccination, by End-users USD Million (2018-2023)
  • Table 34. China GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 35. Japan GP Vaccination, by Type USD Million (2018-2023)
  • Table 36. Japan GP Vaccination, by End-users USD Million (2018-2023)
  • Table 37. Japan GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 38. India GP Vaccination, by Type USD Million (2018-2023)
  • Table 39. India GP Vaccination, by End-users USD Million (2018-2023)
  • Table 40. India GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 41. South Korea GP Vaccination, by Type USD Million (2018-2023)
  • Table 42. South Korea GP Vaccination, by End-users USD Million (2018-2023)
  • Table 43. South Korea GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 44. Australia GP Vaccination, by Type USD Million (2018-2023)
  • Table 45. Australia GP Vaccination, by End-users USD Million (2018-2023)
  • Table 46. Australia GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific GP Vaccination, by Type USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific GP Vaccination, by End-users USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 50. Europe GP Vaccination, by Country USD Million (2018-2023)
  • Table 51. Europe GP Vaccination, by Type USD Million (2018-2023)
  • Table 52. Europe GP Vaccination, by End-users USD Million (2018-2023)
  • Table 53. Europe GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 54. Germany GP Vaccination, by Type USD Million (2018-2023)
  • Table 55. Germany GP Vaccination, by End-users USD Million (2018-2023)
  • Table 56. Germany GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 57. France GP Vaccination, by Type USD Million (2018-2023)
  • Table 58. France GP Vaccination, by End-users USD Million (2018-2023)
  • Table 59. France GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 60. Italy GP Vaccination, by Type USD Million (2018-2023)
  • Table 61. Italy GP Vaccination, by End-users USD Million (2018-2023)
  • Table 62. Italy GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 63. United Kingdom GP Vaccination, by Type USD Million (2018-2023)
  • Table 64. United Kingdom GP Vaccination, by End-users USD Million (2018-2023)
  • Table 65. United Kingdom GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 66. Netherlands GP Vaccination, by Type USD Million (2018-2023)
  • Table 67. Netherlands GP Vaccination, by End-users USD Million (2018-2023)
  • Table 68. Netherlands GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 69. Rest of Europe GP Vaccination, by Type USD Million (2018-2023)
  • Table 70. Rest of Europe GP Vaccination, by End-users USD Million (2018-2023)
  • Table 71. Rest of Europe GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 72. MEA GP Vaccination, by Country USD Million (2018-2023)
  • Table 73. MEA GP Vaccination, by Type USD Million (2018-2023)
  • Table 74. MEA GP Vaccination, by End-users USD Million (2018-2023)
  • Table 75. MEA GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 76. Middle East GP Vaccination, by Type USD Million (2018-2023)
  • Table 77. Middle East GP Vaccination, by End-users USD Million (2018-2023)
  • Table 78. Middle East GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 79. Africa GP Vaccination, by Type USD Million (2018-2023)
  • Table 80. Africa GP Vaccination, by End-users USD Million (2018-2023)
  • Table 81. Africa GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 82. North America GP Vaccination, by Country USD Million (2018-2023)
  • Table 83. North America GP Vaccination, by Type USD Million (2018-2023)
  • Table 84. North America GP Vaccination, by End-users USD Million (2018-2023)
  • Table 85. North America GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 86. United States GP Vaccination, by Type USD Million (2018-2023)
  • Table 87. United States GP Vaccination, by End-users USD Million (2018-2023)
  • Table 88. United States GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 89. Canada GP Vaccination, by Type USD Million (2018-2023)
  • Table 90. Canada GP Vaccination, by End-users USD Million (2018-2023)
  • Table 91. Canada GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 92. Mexico GP Vaccination, by Type USD Million (2018-2023)
  • Table 93. Mexico GP Vaccination, by End-users USD Million (2018-2023)
  • Table 94. Mexico GP Vaccination, by Vaccine USD Million (2018-2023)
  • Table 95. GP Vaccination Sales: by Type(N)
  • Table 96. GP Vaccination Sales DNA , by Region N (2018-2023)
  • Table 97. GP Vaccination Sales Non-replicating Viral Vector , by Region N (2018-2023)
  • Table 98. GP Vaccination Sales RNA , by Region N (2018-2023)
  • Table 99. GP Vaccination Sales Others , by Region N (2018-2023)
  • Table 100. GP Vaccination Sales: by End-users(N)
  • Table 101. GP Vaccination Sales Adults , by Region N (2018-2023)
  • Table 102. GP Vaccination Sales Children , by Region N (2018-2023)
  • Table 103. GP Vaccination Sales: by Vaccine(N)
  • Table 104. GP Vaccination Sales Corbevax Vaccine , by Region N (2018-2023)
  • Table 105. GP Vaccination Sales Covaxin Vaccine , by Region N (2018-2023)
  • Table 106. GP Vaccination Sales Covishield Vaccine , by Region N (2018-2023)
  • Table 107. GP Vaccination Sales Sputnik Light Vaccine , by Region N (2018-2023)
  • Table 108. GP Vaccination Sales Others , by Region N (2018-2023)
  • Table 109. South America GP Vaccination Sales, by Country N (2018-2023)
  • Table 110. South America GP Vaccination Sales, by Type N (2018-2023)
  • Table 111. South America GP Vaccination Sales, by End-users N (2018-2023)
  • Table 112. South America GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 113. Brazil GP Vaccination Sales, by Type N (2018-2023)
  • Table 114. Brazil GP Vaccination Sales, by End-users N (2018-2023)
  • Table 115. Brazil GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 116. Argentina GP Vaccination Sales, by Type N (2018-2023)
  • Table 117. Argentina GP Vaccination Sales, by End-users N (2018-2023)
  • Table 118. Argentina GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 119. Rest of South America GP Vaccination Sales, by Type N (2018-2023)
  • Table 120. Rest of South America GP Vaccination Sales, by End-users N (2018-2023)
  • Table 121. Rest of South America GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 122. Asia Pacific GP Vaccination Sales, by Country N (2018-2023)
  • Table 123. Asia Pacific GP Vaccination Sales, by Type N (2018-2023)
  • Table 124. Asia Pacific GP Vaccination Sales, by End-users N (2018-2023)
  • Table 125. Asia Pacific GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 126. China GP Vaccination Sales, by Type N (2018-2023)
  • Table 127. China GP Vaccination Sales, by End-users N (2018-2023)
  • Table 128. China GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 129. Japan GP Vaccination Sales, by Type N (2018-2023)
  • Table 130. Japan GP Vaccination Sales, by End-users N (2018-2023)
  • Table 131. Japan GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 132. India GP Vaccination Sales, by Type N (2018-2023)
  • Table 133. India GP Vaccination Sales, by End-users N (2018-2023)
  • Table 134. India GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 135. South Korea GP Vaccination Sales, by Type N (2018-2023)
  • Table 136. South Korea GP Vaccination Sales, by End-users N (2018-2023)
  • Table 137. South Korea GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 138. Australia GP Vaccination Sales, by Type N (2018-2023)
  • Table 139. Australia GP Vaccination Sales, by End-users N (2018-2023)
  • Table 140. Australia GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 141. Rest of Asia-Pacific GP Vaccination Sales, by Type N (2018-2023)
  • Table 142. Rest of Asia-Pacific GP Vaccination Sales, by End-users N (2018-2023)
  • Table 143. Rest of Asia-Pacific GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 144. Europe GP Vaccination Sales, by Country N (2018-2023)
  • Table 145. Europe GP Vaccination Sales, by Type N (2018-2023)
  • Table 146. Europe GP Vaccination Sales, by End-users N (2018-2023)
  • Table 147. Europe GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 148. Germany GP Vaccination Sales, by Type N (2018-2023)
  • Table 149. Germany GP Vaccination Sales, by End-users N (2018-2023)
  • Table 150. Germany GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 151. France GP Vaccination Sales, by Type N (2018-2023)
  • Table 152. France GP Vaccination Sales, by End-users N (2018-2023)
  • Table 153. France GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 154. Italy GP Vaccination Sales, by Type N (2018-2023)
  • Table 155. Italy GP Vaccination Sales, by End-users N (2018-2023)
  • Table 156. Italy GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 157. United Kingdom GP Vaccination Sales, by Type N (2018-2023)
  • Table 158. United Kingdom GP Vaccination Sales, by End-users N (2018-2023)
  • Table 159. United Kingdom GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 160. Netherlands GP Vaccination Sales, by Type N (2018-2023)
  • Table 161. Netherlands GP Vaccination Sales, by End-users N (2018-2023)
  • Table 162. Netherlands GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 163. Rest of Europe GP Vaccination Sales, by Type N (2018-2023)
  • Table 164. Rest of Europe GP Vaccination Sales, by End-users N (2018-2023)
  • Table 165. Rest of Europe GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 166. MEA GP Vaccination Sales, by Country N (2018-2023)
  • Table 167. MEA GP Vaccination Sales, by Type N (2018-2023)
  • Table 168. MEA GP Vaccination Sales, by End-users N (2018-2023)
  • Table 169. MEA GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 170. Middle East GP Vaccination Sales, by Type N (2018-2023)
  • Table 171. Middle East GP Vaccination Sales, by End-users N (2018-2023)
  • Table 172. Middle East GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 173. Africa GP Vaccination Sales, by Type N (2018-2023)
  • Table 174. Africa GP Vaccination Sales, by End-users N (2018-2023)
  • Table 175. Africa GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 176. North America GP Vaccination Sales, by Country N (2018-2023)
  • Table 177. North America GP Vaccination Sales, by Type N (2018-2023)
  • Table 178. North America GP Vaccination Sales, by End-users N (2018-2023)
  • Table 179. North America GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 180. United States GP Vaccination Sales, by Type N (2018-2023)
  • Table 181. United States GP Vaccination Sales, by End-users N (2018-2023)
  • Table 182. United States GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 183. Canada GP Vaccination Sales, by Type N (2018-2023)
  • Table 184. Canada GP Vaccination Sales, by End-users N (2018-2023)
  • Table 185. Canada GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 186. Mexico GP Vaccination Sales, by Type N (2018-2023)
  • Table 187. Mexico GP Vaccination Sales, by End-users N (2018-2023)
  • Table 188. Mexico GP Vaccination Sales, by Vaccine N (2018-2023)
  • Table 189. GP Vaccination: by Type(USD/Units)
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. GP Vaccination: by Type(USD Million)
  • Table 201. GP Vaccination DNA , by Region USD Million (2025-2030)
  • Table 202. GP Vaccination Non-replicating Viral Vector , by Region USD Million (2025-2030)
  • Table 203. GP Vaccination RNA , by Region USD Million (2025-2030)
  • Table 204. GP Vaccination Others , by Region USD Million (2025-2030)
  • Table 205. GP Vaccination: by End-users(USD Million)
  • Table 206. GP Vaccination Adults , by Region USD Million (2025-2030)
  • Table 207. GP Vaccination Children , by Region USD Million (2025-2030)
  • Table 208. GP Vaccination: by Vaccine(USD Million)
  • Table 209. GP Vaccination Corbevax Vaccine , by Region USD Million (2025-2030)
  • Table 210. GP Vaccination Covaxin Vaccine , by Region USD Million (2025-2030)
  • Table 211. GP Vaccination Covishield Vaccine , by Region USD Million (2025-2030)
  • Table 212. GP Vaccination Sputnik Light Vaccine , by Region USD Million (2025-2030)
  • Table 213. GP Vaccination Others , by Region USD Million (2025-2030)
  • Table 214. South America GP Vaccination, by Country USD Million (2025-2030)
  • Table 215. South America GP Vaccination, by Type USD Million (2025-2030)
  • Table 216. South America GP Vaccination, by End-users USD Million (2025-2030)
  • Table 217. South America GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 218. Brazil GP Vaccination, by Type USD Million (2025-2030)
  • Table 219. Brazil GP Vaccination, by End-users USD Million (2025-2030)
  • Table 220. Brazil GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 221. Argentina GP Vaccination, by Type USD Million (2025-2030)
  • Table 222. Argentina GP Vaccination, by End-users USD Million (2025-2030)
  • Table 223. Argentina GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 224. Rest of South America GP Vaccination, by Type USD Million (2025-2030)
  • Table 225. Rest of South America GP Vaccination, by End-users USD Million (2025-2030)
  • Table 226. Rest of South America GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 227. Asia Pacific GP Vaccination, by Country USD Million (2025-2030)
  • Table 228. Asia Pacific GP Vaccination, by Type USD Million (2025-2030)
  • Table 229. Asia Pacific GP Vaccination, by End-users USD Million (2025-2030)
  • Table 230. Asia Pacific GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 231. China GP Vaccination, by Type USD Million (2025-2030)
  • Table 232. China GP Vaccination, by End-users USD Million (2025-2030)
  • Table 233. China GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 234. Japan GP Vaccination, by Type USD Million (2025-2030)
  • Table 235. Japan GP Vaccination, by End-users USD Million (2025-2030)
  • Table 236. Japan GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 237. India GP Vaccination, by Type USD Million (2025-2030)
  • Table 238. India GP Vaccination, by End-users USD Million (2025-2030)
  • Table 239. India GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 240. South Korea GP Vaccination, by Type USD Million (2025-2030)
  • Table 241. South Korea GP Vaccination, by End-users USD Million (2025-2030)
  • Table 242. South Korea GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 243. Australia GP Vaccination, by Type USD Million (2025-2030)
  • Table 244. Australia GP Vaccination, by End-users USD Million (2025-2030)
  • Table 245. Australia GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 246. Rest of Asia-Pacific GP Vaccination, by Type USD Million (2025-2030)
  • Table 247. Rest of Asia-Pacific GP Vaccination, by End-users USD Million (2025-2030)
  • Table 248. Rest of Asia-Pacific GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 249. Europe GP Vaccination, by Country USD Million (2025-2030)
  • Table 250. Europe GP Vaccination, by Type USD Million (2025-2030)
  • Table 251. Europe GP Vaccination, by End-users USD Million (2025-2030)
  • Table 252. Europe GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 253. Germany GP Vaccination, by Type USD Million (2025-2030)
  • Table 254. Germany GP Vaccination, by End-users USD Million (2025-2030)
  • Table 255. Germany GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 256. France GP Vaccination, by Type USD Million (2025-2030)
  • Table 257. France GP Vaccination, by End-users USD Million (2025-2030)
  • Table 258. France GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 259. Italy GP Vaccination, by Type USD Million (2025-2030)
  • Table 260. Italy GP Vaccination, by End-users USD Million (2025-2030)
  • Table 261. Italy GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 262. United Kingdom GP Vaccination, by Type USD Million (2025-2030)
  • Table 263. United Kingdom GP Vaccination, by End-users USD Million (2025-2030)
  • Table 264. United Kingdom GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 265. Netherlands GP Vaccination, by Type USD Million (2025-2030)
  • Table 266. Netherlands GP Vaccination, by End-users USD Million (2025-2030)
  • Table 267. Netherlands GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 268. Rest of Europe GP Vaccination, by Type USD Million (2025-2030)
  • Table 269. Rest of Europe GP Vaccination, by End-users USD Million (2025-2030)
  • Table 270. Rest of Europe GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 271. MEA GP Vaccination, by Country USD Million (2025-2030)
  • Table 272. MEA GP Vaccination, by Type USD Million (2025-2030)
  • Table 273. MEA GP Vaccination, by End-users USD Million (2025-2030)
  • Table 274. MEA GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 275. Middle East GP Vaccination, by Type USD Million (2025-2030)
  • Table 276. Middle East GP Vaccination, by End-users USD Million (2025-2030)
  • Table 277. Middle East GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 278. Africa GP Vaccination, by Type USD Million (2025-2030)
  • Table 279. Africa GP Vaccination, by End-users USD Million (2025-2030)
  • Table 280. Africa GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 281. North America GP Vaccination, by Country USD Million (2025-2030)
  • Table 282. North America GP Vaccination, by Type USD Million (2025-2030)
  • Table 283. North America GP Vaccination, by End-users USD Million (2025-2030)
  • Table 284. North America GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 285. United States GP Vaccination, by Type USD Million (2025-2030)
  • Table 286. United States GP Vaccination, by End-users USD Million (2025-2030)
  • Table 287. United States GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 288. Canada GP Vaccination, by Type USD Million (2025-2030)
  • Table 289. Canada GP Vaccination, by End-users USD Million (2025-2030)
  • Table 290. Canada GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 291. Mexico GP Vaccination, by Type USD Million (2025-2030)
  • Table 292. Mexico GP Vaccination, by End-users USD Million (2025-2030)
  • Table 293. Mexico GP Vaccination, by Vaccine USD Million (2025-2030)
  • Table 294. GP Vaccination Sales: by Type(N)
  • Table 295. GP Vaccination Sales DNA , by Region N (2025-2030)
  • Table 296. GP Vaccination Sales Non-replicating Viral Vector , by Region N (2025-2030)
  • Table 297. GP Vaccination Sales RNA , by Region N (2025-2030)
  • Table 298. GP Vaccination Sales Others , by Region N (2025-2030)
  • Table 299. GP Vaccination Sales: by End-users(N)
  • Table 300. GP Vaccination Sales Adults , by Region N (2025-2030)
  • Table 301. GP Vaccination Sales Children , by Region N (2025-2030)
  • Table 302. GP Vaccination Sales: by Vaccine(N)
  • Table 303. GP Vaccination Sales Corbevax Vaccine , by Region N (2025-2030)
  • Table 304. GP Vaccination Sales Covaxin Vaccine , by Region N (2025-2030)
  • Table 305. GP Vaccination Sales Covishield Vaccine , by Region N (2025-2030)
  • Table 306. GP Vaccination Sales Sputnik Light Vaccine , by Region N (2025-2030)
  • Table 307. GP Vaccination Sales Others , by Region N (2025-2030)
  • Table 308. South America GP Vaccination Sales, by Country N (2025-2030)
  • Table 309. South America GP Vaccination Sales, by Type N (2025-2030)
  • Table 310. South America GP Vaccination Sales, by End-users N (2025-2030)
  • Table 311. South America GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 312. Brazil GP Vaccination Sales, by Type N (2025-2030)
  • Table 313. Brazil GP Vaccination Sales, by End-users N (2025-2030)
  • Table 314. Brazil GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 315. Argentina GP Vaccination Sales, by Type N (2025-2030)
  • Table 316. Argentina GP Vaccination Sales, by End-users N (2025-2030)
  • Table 317. Argentina GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 318. Rest of South America GP Vaccination Sales, by Type N (2025-2030)
  • Table 319. Rest of South America GP Vaccination Sales, by End-users N (2025-2030)
  • Table 320. Rest of South America GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 321. Asia Pacific GP Vaccination Sales, by Country N (2025-2030)
  • Table 322. Asia Pacific GP Vaccination Sales, by Type N (2025-2030)
  • Table 323. Asia Pacific GP Vaccination Sales, by End-users N (2025-2030)
  • Table 324. Asia Pacific GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 325. China GP Vaccination Sales, by Type N (2025-2030)
  • Table 326. China GP Vaccination Sales, by End-users N (2025-2030)
  • Table 327. China GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 328. Japan GP Vaccination Sales, by Type N (2025-2030)
  • Table 329. Japan GP Vaccination Sales, by End-users N (2025-2030)
  • Table 330. Japan GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 331. India GP Vaccination Sales, by Type N (2025-2030)
  • Table 332. India GP Vaccination Sales, by End-users N (2025-2030)
  • Table 333. India GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 334. South Korea GP Vaccination Sales, by Type N (2025-2030)
  • Table 335. South Korea GP Vaccination Sales, by End-users N (2025-2030)
  • Table 336. South Korea GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 337. Australia GP Vaccination Sales, by Type N (2025-2030)
  • Table 338. Australia GP Vaccination Sales, by End-users N (2025-2030)
  • Table 339. Australia GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 340. Rest of Asia-Pacific GP Vaccination Sales, by Type N (2025-2030)
  • Table 341. Rest of Asia-Pacific GP Vaccination Sales, by End-users N (2025-2030)
  • Table 342. Rest of Asia-Pacific GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 343. Europe GP Vaccination Sales, by Country N (2025-2030)
  • Table 344. Europe GP Vaccination Sales, by Type N (2025-2030)
  • Table 345. Europe GP Vaccination Sales, by End-users N (2025-2030)
  • Table 346. Europe GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 347. Germany GP Vaccination Sales, by Type N (2025-2030)
  • Table 348. Germany GP Vaccination Sales, by End-users N (2025-2030)
  • Table 349. Germany GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 350. France GP Vaccination Sales, by Type N (2025-2030)
  • Table 351. France GP Vaccination Sales, by End-users N (2025-2030)
  • Table 352. France GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 353. Italy GP Vaccination Sales, by Type N (2025-2030)
  • Table 354. Italy GP Vaccination Sales, by End-users N (2025-2030)
  • Table 355. Italy GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 356. United Kingdom GP Vaccination Sales, by Type N (2025-2030)
  • Table 357. United Kingdom GP Vaccination Sales, by End-users N (2025-2030)
  • Table 358. United Kingdom GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 359. Netherlands GP Vaccination Sales, by Type N (2025-2030)
  • Table 360. Netherlands GP Vaccination Sales, by End-users N (2025-2030)
  • Table 361. Netherlands GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 362. Rest of Europe GP Vaccination Sales, by Type N (2025-2030)
  • Table 363. Rest of Europe GP Vaccination Sales, by End-users N (2025-2030)
  • Table 364. Rest of Europe GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 365. MEA GP Vaccination Sales, by Country N (2025-2030)
  • Table 366. MEA GP Vaccination Sales, by Type N (2025-2030)
  • Table 367. MEA GP Vaccination Sales, by End-users N (2025-2030)
  • Table 368. MEA GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 369. Middle East GP Vaccination Sales, by Type N (2025-2030)
  • Table 370. Middle East GP Vaccination Sales, by End-users N (2025-2030)
  • Table 371. Middle East GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 372. Africa GP Vaccination Sales, by Type N (2025-2030)
  • Table 373. Africa GP Vaccination Sales, by End-users N (2025-2030)
  • Table 374. Africa GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 375. North America GP Vaccination Sales, by Country N (2025-2030)
  • Table 376. North America GP Vaccination Sales, by Type N (2025-2030)
  • Table 377. North America GP Vaccination Sales, by End-users N (2025-2030)
  • Table 378. North America GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 379. United States GP Vaccination Sales, by Type N (2025-2030)
  • Table 380. United States GP Vaccination Sales, by End-users N (2025-2030)
  • Table 381. United States GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 382. Canada GP Vaccination Sales, by Type N (2025-2030)
  • Table 383. Canada GP Vaccination Sales, by End-users N (2025-2030)
  • Table 384. Canada GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 385. Mexico GP Vaccination Sales, by Type N (2025-2030)
  • Table 386. Mexico GP Vaccination Sales, by End-users N (2025-2030)
  • Table 387. Mexico GP Vaccination Sales, by Vaccine N (2025-2030)
  • Table 388. GP Vaccination: by Type(USD/Units)
  • Table 389. Research Programs/Design for This Report
  • Table 390. Key Data Information from Secondary Sources
  • Table 391. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global GP Vaccination: by Type USD Million (2018-2023)
  • Figure 5. Global GP Vaccination: by End-users USD Million (2018-2023)
  • Figure 6. Global GP Vaccination: by Vaccine USD Million (2018-2023)
  • Figure 7. South America GP Vaccination Share (%), by Country
  • Figure 8. Asia Pacific GP Vaccination Share (%), by Country
  • Figure 9. Europe GP Vaccination Share (%), by Country
  • Figure 10. MEA GP Vaccination Share (%), by Country
  • Figure 11. North America GP Vaccination Share (%), by Country
  • Figure 12. Global GP Vaccination: by Type N (2018-2023)
  • Figure 13. Global GP Vaccination: by End-users N (2018-2023)
  • Figure 14. Global GP Vaccination: by Vaccine N (2018-2023)
  • Figure 15. South America GP Vaccination Share (%), by Country
  • Figure 16. Asia Pacific GP Vaccination Share (%), by Country
  • Figure 17. Europe GP Vaccination Share (%), by Country
  • Figure 18. MEA GP Vaccination Share (%), by Country
  • Figure 19. North America GP Vaccination Share (%), by Country
  • Figure 20. Global GP Vaccination: by Type USD/Units (2018-2023)
  • Figure 21. Global GP Vaccination share by Players 2023 (%)
  • Figure 22. Global GP Vaccination share by Players (Top 3) 2023(%)
  • Figure 23. Global GP Vaccination share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. GlaxoSmithKine (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKine (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer (United States) Revenue: by Geography 2023
  • Figure 29. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 31. Heat Biologics (United States) Revenue, Net Income and Gross profit
  • Figure 32. Heat Biologics (United States) Revenue: by Geography 2023
  • Figure 33. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi (France) Revenue: by Geography 2023
  • Figure 35. Takis Biotech (Italy) Revenue, Net Income and Gross profit
  • Figure 36. Takis Biotech (Italy) Revenue: by Geography 2023
  • Figure 37. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 38. Zydus Cadila (India) Revenue: by Geography 2023
  • Figure 39. Codagenix (United States) Revenue, Net Income and Gross profit
  • Figure 40. Codagenix (United States) Revenue: by Geography 2023
  • Figure 41. GeoVax (United States) Revenue, Net Income and Gross profit
  • Figure 42. GeoVax (United States) Revenue: by Geography 2023
  • Figure 43. Bravovax (China) Revenue, Net Income and Gross profit
  • Figure 44. Bravovax (China) Revenue: by Geography 2023
  • Figure 45. Global GP Vaccination: by Type USD Million (2025-2030)
  • Figure 46. Global GP Vaccination: by End-users USD Million (2025-2030)
  • Figure 47. Global GP Vaccination: by Vaccine USD Million (2025-2030)
  • Figure 48. South America GP Vaccination Share (%), by Country
  • Figure 49. Asia Pacific GP Vaccination Share (%), by Country
  • Figure 50. Europe GP Vaccination Share (%), by Country
  • Figure 51. MEA GP Vaccination Share (%), by Country
  • Figure 52. North America GP Vaccination Share (%), by Country
  • Figure 53. Global GP Vaccination: by Type N (2025-2030)
  • Figure 54. Global GP Vaccination: by End-users N (2025-2030)
  • Figure 55. Global GP Vaccination: by Vaccine N (2025-2030)
  • Figure 56. South America GP Vaccination Share (%), by Country
  • Figure 57. Asia Pacific GP Vaccination Share (%), by Country
  • Figure 58. Europe GP Vaccination Share (%), by Country
  • Figure 59. MEA GP Vaccination Share (%), by Country
  • Figure 60. North America GP Vaccination Share (%), by Country
  • Figure 61. Global GP Vaccination: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKine (United Kingdom)
  • Pfizer (United States)
  • Johnson & Johnson (United States)
  • Heat Biologics (United States)
  • Sanofi (France)
  • Takis Biotech (Italy)
  • Zydus Cadila (India)
  • Codagenix (United States)
  • GeoVax (United States)
  • Bravovax (China)
Additional players considered in the study are as follows:
Altimmune (United States) , Vaxart (United States) , Clover Biopharmaceuticals (China) , ImmunoPrecise (Canada)
Select User Access Type

Key Highlights of Report


Feb 2024 247 Pages 95 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global GP Vaccination Market Quantitative research analysis
Global GP Vaccination Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKine (United Kingdom), Pfizer (United States), Johnson & Johnson (United States), Heat Biologics (United States), Sanofi (France), Takis Biotech (Italy), Zydus Cadila (India), Codagenix (United States), GeoVax (United States) and Bravovax (China) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing demand for Low-priced Vaccines " is seen as one of major influencing trends for GP Vaccination Market during projected period 2023-2030.
The GP Vaccination market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global GP Vaccination Market Report?

Have a Query? Click Here

Other Related Reports

Catalepsy Treatment Comprehensive Study by Treatment (Antipsychotic medications {Drugs, Psychotherapy, Others}, Muscle relaxants), Route of Administration (Oral, Parenteral, Others), End-Users (Hos...
$ 3800
Vasoconstrictor Drugs Comprehensive Study by Application (Clinic, Hospital), Administration (Intravenous, Oral), Side Effect (Irregular Heartbeats, Dizziness, Diarrhea, High Blood Sugar), Distributi...
$ 3800
Zip Stitches Comprehensive Study by Application (Sports Injury Treatment, Surgical Wound Treatment, Traumatic Wound Treatment, Ulcer Treatment), Distribution Channel (Online {Company Website, E-Comme...
$ 3500
Acne Vulgaris Drug Comprehensive Study by Type (Comedonal, Inflammatory, Cystic, Postsurgical/Wound), Drug Type (OTC Drugs, Prescription Drugs), Drug Class (Retinoids, Antibiotics, Hormonal Agents, C...
$ 3800
Cardiac Medication Comprehensive Study by Type (Anticoagulants, Antiplatelet medications, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin receptor blockers (ARBs)), Application (Hospitals...
$ 3800
Multi-Dose Medication Comprehensive Study by End-users (Hospitals & Clinics, Pharmacies, Others), Software (Computerized Physician Order Entry, Clinical Decision Support System, Automated Dispensing ...
$ 3500